Next Article in Journal
High Throughput Chemical Screening Reveals Multiple Regulatory Proteins on FOXA1 in Breast Cancer Cell Lines
Next Article in Special Issue
The Epithelial-Mesenchymal Transition Initiated by Malignant Ascites Underlies the Transmesothelial Invasion of Ovarian Cancer Cells
Previous Article in Journal
Hydrogen Sulfide: A Therapeutic Option in Systemic Sclerosis
Previous Article in Special Issue
Interstitial Fluid in Gynecologic Tumors and Its Possible Application in the Clinical Practice
Open AccessPerspective

S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer

1
Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide 5005, Australia
2
Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(12), 4122; https://doi.org/10.3390/ijms19124122
Received: 5 November 2018 / Revised: 4 December 2018 / Accepted: 17 December 2018 / Published: 19 December 2018
S100A10, which is also known as p11, is located in the plasma membrane and forms a heterotetramer with annexin A2. The heterotetramer, comprising of two subunits of annexin A2 and S100A10, activates the plasminogen activation pathway, which is involved in cellular repair of normal tissues. Increased expression of annexin A2 and S100A10 in cancer cells leads to increased levels of plasmin—which promotes the degradation of the extracellular matrix—increased angiogenesis, and the invasion of the surrounding organs. Although many studies have investigated the functional role of annexin A2 in cancer cells, including ovarian cancer, S100A10 has been less studied. We recently demonstrated that high stromal annexin A2 and high cytoplasmic S100A10 expression is associated with a 3.4-fold increased risk of progression and 7.9-fold risk of death in ovarian cancer patients. Other studies have linked S100A10 with multidrug resistance in ovarian cancer; however, no functional studies to date have been performed in ovarian cancer cells. This article reviews the current understanding of S100A10 function in cancer with a particular focus on ovarian cancer. View Full-Text
Keywords: S100A10; annexin A2; plasmin; ovarian cancer; chemotherapy resistance S100A10; annexin A2; plasmin; ovarian cancer; chemotherapy resistance
Show Figures

Figure 1

MDPI and ACS Style

Noye, T.M.; Lokman, N.A.; Oehler, M.K.; Ricciardelli, C. S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer. Int. J. Mol. Sci. 2018, 19, 4122.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop